Let’s start with a
patient case. A patient is admitted to
the hospital with a CHF exacerbation.
They are taking warfarin for atrial fibrillation and their coagulation
panel reveals an INR of 8. What are our options
for administering vitamin K and some of the nuances for each route of
administration?
Scenarios similar to
this are common occurrences in the internal medicine setting as heart failure
is an independent risk factor for overanticoagulation. The decision whether or not to use vitamin K
should be based on several factors which will not be addressed now.
Vitamin K can be
administered by the oral, intravenous, intramuscular, or subcutaneous
routes. Vitamin K is a fat-soluble
vitamin of which there are two types; one we find in green vegetables (and lots
of other foods) and the other is synthesized by intestinal bacteria. The vitamin K that we give for therapeutic
use is the former, phytonadione.1